Covera-hs is a drug owned by Pfizer Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 04, 2017. Details of Covera-hs's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6096339 | Dosage form, process of making and using same |
Apr, 2017
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Covera-hs is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Covera-hs's family patents as well as insights into ongoing legal events on those patents.
Covera-hs's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Covera-hs's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 04, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Covera-hs Generic API suppliers:
Verapamil Hydrochloride is the generic name for the brand Covera-hs. 36 different companies have already filed for the generic of Covera-hs, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Covera-hs's generic
How can I launch a generic of Covera-hs before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Covera-hs's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Covera-hs's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Covera-hs -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 240 mg |
Alternative Brands for Covera-hs
Covera-hs which is used for treating cardiovascular disease through the administration of a calcium blocking vasodilator., has several other brand drugs using the same active ingredient (Verapamil Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Verapamil Hydrochloride, Covera-hs's active ingredient. Check the complete list of approved generic manufacturers for Covera-hs
About Covera-hs
Covera-Hs is a drug owned by Pfizer Inc. It is used for treating cardiovascular disease through the administration of a calcium blocking vasodilator. Covera-Hs uses Verapamil Hydrochloride as an active ingredient. Covera-Hs was launched by Pfizer in 1996.
Approval Date:
Covera-hs was approved by FDA for market use on 26 February, 1996.
Active Ingredient:
Covera-hs uses Verapamil Hydrochloride as the active ingredient. Check out other Drugs and Companies using Verapamil Hydrochloride ingredient
Treatment:
Covera-hs is used for treating cardiovascular disease through the administration of a calcium blocking vasodilator.
Dosage:
Covera-hs is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 180MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 240MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |